Skip to content

A prospective self-control study of Chinese herbal acupoint therapy in the treatment of chronic kidney disease­ associated pruritus

A prospective self-control study of Chinese herbal acupoint therapy in the treatment of chronic kidney disease­ associated pruritus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001982
Enrollment
Unknown
Registered
2025-10-22
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease-associated pruritus

Interventions

Single-arm trial:The traditional Chinese medicine herbal preparation (comprising Portulaca oleracea Phellodendron amurense Sanguisorba officinalis Lithospermum erythrorhizon Salvia miltiorrhiza Sophor

Sponsors

People's Hospital of Youyang Tujia and Miao autonomous county of chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age =18 years. 2.Non-dialysis subjects with moderate renal impairment (estimated glomerular filtration rate [eGFR] =30 and <60 mL/min/1.73 m²) or severe renal impairment (eGFR <30 mL/min/1.73 m²). 3.Hemodialysis subjects receiving hemodialysis 3 times per week for =3 months prior to screening. 4.Pruritus severity: Skin itching occurring on at least 3 days within a 2-week period with moderate-to-severe pruritus defined as a baseline Worst Itching Intensity Numeric Rating Scale (WI-NRS) score =5. 5.Exclusion of non-CKD causes: During the 7-day run-in period prior to TCM topical treatment subjects with pruritus attributable to causes other than chronic kidney disease (CKD) were excluded. 6.Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1.Concurrent primary skin disorders (e.g. eczema psoriasis neurodermatitis allergic dermatitis drug-induced rash etc.). 2.Use of medications such as dextran analgesics antibiotics or lipid-lowering drugs. 3.Comorbid conditions including peripheral neuropathy thyroid disorders leukemia lymphoma cholestasis pregnancy or hearing/communication impairments that prevent completion of the study assessments.

Design outcomes

Primary

MeasureTime frame
Worst Itching Intensity Numeric Rating Scale, WI-NRS;

Secondary

MeasureTime frame
Proportion of subjects achieving a =3-point improvement in weekly average WI-NRS score from baseline;Change in the Skindex-10 total score from baseline to Week 12 of treatment.;Change in the 5-D Itch Scale total score from baseline to Week 12 of treatment.;Proportion of subjects with a WI-NRS score improvement of =4 points;Proportion of subjects achieving complete resolution of pruritus, defined as a WI-NRS score of 0 or 1.;Change from baseline in weekly WI-NRS score.;Change from baseline in the weekly 5-D Itch Scale total score.;Weekly change from baseline in the Skindex-10 total score.;Serum Creatinine ;Serum Calcium;Serum Phosphorus; Intact Parathyroid Hormone ;Serum Beta-2 Microglobulin;C-Reactive Protein;Ferritin;Interleukin-1;Interleukin-6;

Countries

China

Contacts

Public ContactJing Guo

People's Hospital of Youyang Tujia and Miao autonomous county of chongqing

314335376@qq.com13648259745

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026